Title : The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer.

Pub. Date : 2019

PMID : 31608224






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Patients" clinical factors and genetics factors such as anaplastic lymphoma kinase (ALK) fusion variants and BIM (Bcl-2-like 11) polymorphism were reported to be associated with clinical outcome in crizotinib-treated advanced non-small cell lung cancer (NSCLC). Crizotinib BCL2 like 11 Homo sapiens